TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21526662
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI)
Study: 14661563
Drug: Intravenous flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous flurbiprofen 50 mg
Study: 14661563
Drug: Suppository indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository indomethacin 50 mg
Study: 11340886
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:200,000 epinephrine and 1 ml of 7.5% sodium bicarbonate
Study: 11340886
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:200,000 epinephrine and 450 units of hyaluronidase (15 U/ml)
Study: 8772331
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of oral salbutamol
Study: 1602191
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (MDT + 8 intradermal injections of M. w. every 3 months)
Study: 1602191
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (MDT + starch injections as placebo)
Study: 30809967
Drug: Chiglitazar (CHI)
Normalized name: Ma Chi Xian
DrugBank: Chiglitazar (DB19023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar (CHI) 48 mg
Study: 30809967
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin Hydrochloride (MET) 1000 mg
Study: 30809967
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CHI and MET
Study: 30303516
Drug: Ziv-aflibercept and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziv-aflibercept and high-dose interleukin 2 (arm A)
Study: 30303516
Drug: High-dose interleukin
Normalized name: interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin 2 alone (arm B)
Study: 22705426
Drug: Daily distribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily distribution of RUF-Nias biscuits
Study: 22705426
Drug: Weekly distribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly distribution of RUF-Nias biscuits
Study: 11954880
Drug: Aspirin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (up to 3g daily)
Study: 11954880
Drug: Paracetamol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (up to 3g daily)
Study: 11954880
Drug: Ibuprofen (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (up to 1.2g daily)
Study: 7751888
Drug: Thoracic XRT
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic XRT with cisplatin 70 mg/m2 every 3 weeks for three cycles
Study: 7751888
Drug: Thoracic XRT
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic XRT alone, 60 to 65 Gy total tumor dose in daily fractions of 1.80 to 2.00 Gy
Study: 2113611
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg) daily on days 4 through 17
Study: 2113611
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg) (groups 3 and 4 combined)
Study: 2113611
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg) (in subgroup with lowest spinal bone mineral density)
Study: 2113611
Drug: Phosphate (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate (1.0 g) twice daily on days 1 through 3
Study: 31973645
Drug: Palliative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative care services provided by a multiprofessional team in the hospital, villages, and homes; short-acting morphine oral solution as the only available strong opioid.
Study: 31083190
Drug: Neuroendoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroendoscopic treatment guided by body surface projection
Study: 25988553
Drug: Fish oil-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil-enriched dairy drink (400 mL/day)
Study: 25988553
Drug: Control dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control dairy drink (400 mL/day)
Study: 21700966
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition supplemented with ω‐3 and ω‐6 fatty acids (Omegaven, 0.2 g/kg/d; Lipovenoes 10%, 0.6 g/kg/d)
Study: 21700966
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition with ω‐6 fatty acid (Lipovenoes 10%, 0.8 g/kg/d)
Study: 19371322
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1500 mg tomopenem
Study: 16513616
Drug: Single-phase whole-body
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-phase whole-body CT scan (90 mL at 1.8 mL/min; delay, 90 s) during normal expiration (protocol B)
Study: 16513616
Drug: Single-phase whole-body
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-phase whole-body CT scan (90 mL at 1.8 mL/min; delay, 90 s) during shallow breathing (protocol A)
Study: 12620440
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg b.i.d. with placebo (Group I)
Study: 12620440
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg b.i.d. with clomiphene citrate (Group II)
Study: 10854639
Drug: Venlafaxine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine monotherapy (225 mg, once or twice daily for 6 weeks)
Study: 9093725
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus best supportive care
Study: 8255126
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg
Study: 30211989
Drug: Test dental
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dental gel containing 2.6% edathamil
Study: 15974218
Drug: Control gel
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control gel
Study: 18414647
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg albendazole administered every 6 months for 2 years (5 rounds)
Study: 18414647
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A administered every 6 months
Study: 7901585
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no albendazole treatment)
Study: 11868059
Drug: Niacin 50
Normalized name: niacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 50 mg administered by mouth 2 times daily for 3 months
Study: 9878944
Drug: Tasosartan 50
Normalized name: tasosartan
DrugBank: Tasosartan (DB01349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasosartan 50 mg, increased to 100 mg and then to 200 mg if SiDBP > 90 mm Hg
Study: 7495780
Drug: Interferon-alfa therapy
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alfa therapy (3 MU every day for 3 months)
Study: 7495780
Drug: Interferon-alfa therapy
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alfa therapy (3 MU every other day for 3 months)
Study: 7495780
Drug: Interferon-alfa therapy
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alfa therapy (3 MU every other day for 6 months)
Study: 7495780
Drug: Interferon-alfa therapy
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alfa therapy
Study: 1902264
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous (IV) fentanyl
Study: 7325630
Drug: Amoxicillin 250
Normalized name: amoxicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 250 mg twice daily for 4 weeks
Study: 7325630
Drug: Ampicillin 250
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 250 mg twice daily for 4 weeks
Study: 7325630
Drug: Both Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both Amoxicillin and Ampicillin
Study: 7325630
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and Ampicillin
Study: 23906374
Drug: Empagliflozin 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 1, 5, 10, 25, or 50 mg QD
Study: 23906374
Drug: Empagliflozin 5
Normalized name: empagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 5 to 50 mg QD
Study: 21817188
Drug: Drug conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug conservation (DC; interrupt ART until CD4(+) T-cell count <250)
Study: 15780528
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen replacement therapy (TERT) - 100 microg 17beta‐estradiol (Climara forte TTS) once a week for 3 months
Study: 11900782
Drug: Alcohol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (target peak BAC of 0.05 g/dl)
Study: 10527965
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU recombinant follicle stimulating hormone (recFSH, Puregon)
Study: 10527965
Drug: 225 IU
Normalized name: Ascorbic Acid/Calcium Pantothenate/Cyanocobalamin/Iron/Niacin/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin D/Vitamin E/Zinc 200 MG-18.4 MG-0.005 MG-12 MG-100 MG-4.1 MG-10 MG-0.3 MG-10000 IU-400 IU-225 IU-1.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 IU highly purified urinary follicle stimulating hormone (uFSH-HP, Metrodin-HP)
Study: 7859944
Drug: Insulin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin concentration increased to 416 +/- 22 pmol/l (step I), 1,170 +/- 79 pmol/l (step II), and 15,936 +/- 1,126 pmol/l (step III) in control subjects; LBF increased from 287 +/- 23 ml.min-1.leg-1 (basal) to 308 +/- 31 ml.min-1.leg-1 (I), 371 +/- 29 ml.min-1.leg-1 (II), and 434 +/- 32 ml.min-1.leg-1 (III).
Study: 7859944
Drug: Insulin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin concentration increased to 509 +/- 43 pmol/l (step I), 1,299 +/- 122 pmol/l (step II), and 16,524 +/- 1,916 pmol/l (step III) in NIDDM subjects; LBF increased from 302 +/- 12 ml.min-1.leg-1 (basal) to 362 +/- 9 ml.min-1.leg-1 (I), 409 +/- 17 ml.min-1.leg-1 (II), and 472 +/- 29 ml.min-1.leg-1 (III).
Study: 21555816
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) 200 mg twice daily or 400 mg once daily
Study: 21555816
Drug: Atazanavir/ritonavir (ATZ/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily
Study: 12596616
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg (group 1)
Study: 12596616
Drug: Rocuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.3 mg/kg and Atracurium 0.25 mg/kg (group 2)
Study: 12596616
Drug: Rocuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.1 mg/kg to prime Atracurium 0.42 mg/kg (priming group)
Study: 2698570
Drug: Gallopamil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (3 X 60 mg/day)
Study: 2698570
Drug: Diltiazem (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (3 X 50 mg/day)
Study: 29103741
Drug: Outpatient physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient physical therapy (OPT)
Study: 23241739
Drug: Palifermin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin (60 μg/kg/day) i.v. for 3 consecutive days before high-dose Melphalan (HDM)
Study: 23241739
Drug: Palifermin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin (60 μg/kg/day) i.v. for 3 consecutive days before and after HDM
Study: 16110353
Drug: Astaxanthin 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin 16 mg/day
Study: 12520750
Drug: Intraartery chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraartery chemotherapy with Taxol 135 mg/m2 and DDP 80 mg/m2
Study: 12520750
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy with Taxol 135 mg/m2 and DDP 80 mg/m2
Study: 2506751
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intravenous nitroglycerin
Study: 31833569
Drug: Spironolactone (≤50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (≤50 mg)
Study: 31833569
Drug: Doxazosin (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (control ≤16 mg)
Study: 31833569
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (70 mL, ≤11 mmol nitrate)
Study: 28737971
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone Furoate (FF; 100 μg)
Study: 28737971
Drug: Vilanterol (VI;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol (VI; 25 μg)
Study: 18988166
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg intravitreal bevacizumab (IVB group)
Study: 18988166
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1.25 mg bevacizumab and 2 mg triamcinolone acetonide (IVB+IVT group)
Study: 10530177
Drug: 0.05% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% NaF solution rinsing (n = 49)
Study: 10530177
Drug: 1.66 mg
Normalized name: pyrilamine maleate 1.66 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.66 mg NaF tablet (n = 51)
Study: 2757958
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 5 mg/kg per day
Study: 4817159
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test in the afternoon
Study: 31479045
Drug: Limited Sampling
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Limited Sampling Strategies (LSS) with sampling at 0, 120, 180, and 240 minutes after the start of the second infusion (LSS15)
Study: 27780297
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg Nazolam
Study: 27780297
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg Nazolam
Study: 27780297
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg intravenous midazolam
Study: 25855760
Drug: OAC (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (standard triple therapy)
Study: 25855760
Drug: OA-OACM (hybrid
Approvals — FDA: no, EMA: no, PMDA: no
Description: OA-OACM (hybrid therapy)
Study: 24144653
Drug: Naltrexone sustained-release/bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone sustained-release/bupropion sustained-release (NB)
Study: 11547370
Drug: 5-step lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-step lateral release sequence (PCL, posterolateral capsule, IT band, PT, LCL)
Study: 7800954
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily oral theophylline (800 mg/day)
Study: 7800954
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily inhaled budesonide (0.8 mg/day)
Study: 29546857
Drug: H1-coil rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1-coil rTMS as an add-on to stable pharmacotherapy
Study: 29546857
Drug: Figure-8-coil rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figure-8-coil rTMS as an add-on to stable pharmacotherapy
Study: 29546857
Drug: Stable pharmacotherapy
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable pharmacotherapy alone
Study: 22913800
Drug: Perampanel (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (titrated to a maximum of 12 mg/day over 12 weeks, maintained for up to 424 weeks)
Study: 18435373
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop (LP)
Study: 14655913
Drug: Cabergoline (upward
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (upward titration from 0.5 mg to 2 mg in a single evening dose)
Study: 3888102
Drug: Ribavirin small-particle
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin small-particle aerosol treatment (2.4 g over 42 h during 68 h of hospitalization)
Study: 31574097
Drug: Football group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Football group (FG) - 6 months of free-of-charge football training twice weekly
Study: 26204844
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate (SrR) 2 g daily
Study: 22930293
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal cream (CVC) for three days
Study: 22930293
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal cream (CVC) additional seven-day course
Study: 22930293
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal cream (CVC) additional treatment
Study: 22930293
Drug: Placebo additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo additional treatment
Study: 22930293
Drug: Clindamycin vaginal
Normalized name: clindamycin Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin vaginal cream (CVC)
Study: 20613550
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg 12 hours before PCI, with a further 40 mg preprocedure dose)
Study: 2350209
Drug: Cocaine hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine hydrochloride (40 mg intravenously)
Study: 111274
Drug: Clorgyline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorgyline treatment for 4 weeks
Study: 111274
Drug: Pargyline treatment
Normalized name: pargyline
DrugBank: Pargyline (DB01626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pargyline treatment
Study: 31863189
Drug: Diphenhydramine 30
Normalized name: pseudoephed/diphenhydramine 30 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 30 mg intravenously after induction of general anesthesia
Study: 30504445
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg single infusion)
Study: 25533540
Drug: Pramipexole (PPX)
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramipexole (PPX) 0.25 mg to 0.75 mg, taken 2-3 hours before bedtime for 12 weeks
Study: 11146393
Drug: bivalent HAV/HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent HAV/HBV vaccine
Study: 9557092
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and Gamma‐Venin P
Study: 8354633
Drug: AZT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT treatment
Study: 3524509
Drug: D-phenylalanine (DPA)
Normalized name: Phenylalanine
DrugBank: D-Phenylalanine (DB02556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-phenylalanine (DPA) 250 mg orally four times a day for four weeks
Study: 29128692
Drug: Aspirin 975
Normalized name: aspirin 975 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 975 mg tid and omeprazole 20 mg od
Study: 26155004
Drug: 2% papain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% papain gel
Study: 26155004
Drug: 2% carboxymethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% carboxymethyl cellulose gel
Study: 21814138
Drug: recombinant GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant GH (rGH) administration, 6 IU daily
Study: 19487903
Drug: Nonnucleoside reverse
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonnucleoside reverse transcriptase inhibitor (NNRTI) + protease inhibitor
Study: 19487903
Drug: Classical nucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical nucleoside reverse transcriptase inhibitor (NRTI) based regimen
Study: 15488341
Drug: Oral methylphenidate
Normalized name: methylphenidate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylphenidate (MPH) 0.5 mg/kg
Study: 9475306
Drug: Rice oral
Normalized name: Licorice Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice oral rehydration solution (ORS)
Study: 7524313
Drug: Fresh frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh frozen plasma (FFP) 20 ml/kg
Study: 2856598
Drug: Pirprofen administered
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pirprofen administered by iontophoresis
Study: 2856598
Drug: Lysine soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine soluble aspirin administered by iontophoresis
Study: 25672646
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation (n = 60)
Study: 23534020
Drug: MDPB-containing self-etching
Normalized name: fish oil (containing omega-3 acids)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDPB-containing self-etching primer with fluoride-free bonding agent